Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
J. appl. oral sci ; 27: e20180396, 2019. graf
Artículo en Inglés | LILACS, BBO | ID: biblio-1002404

RESUMEN

Abstract Endodontic revascularization is based on cell recruitment into the necrotic root canal of immature teeth after chemical disinfection. The clinical outcome depends on the ability of surviving cells from the apical tissue to differentiate and promote hard tissue deposition inside the dentinal walls. Objective To investigate the effect of calcium hydroxide (CH) and modified triple antibiotic paste (mTAP - ciprofloxacin, metronidazole and cefaclor) on the viability and mineralization potential of apical papilla cells (APC) in vitro . Material and Methods APC cultures were kept in contact with CH or mTAP (250-1000 µg/mL) for 5 days, after which cell viability was assessed using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Next, APCs were subjected to CH or mTAP at 250 µg/mL for 5 days before inducing the differentiation assay. After 14 and 21 days, calcium deposition was assessed by the Alizarin Red S staining method, followed by elution and quantification using spectrophotometry. Data were analyzed using ANOVA followed by Tukey post hoc test. Results CH induced cell proliferation, whereas mTAP showed significant cytotoxicity at all concentrations tested. APC treated with CH demonstrated improved mineralization capacity at 14 days, while, for mTAP, significant reduction on the mineralization rate was observed for both experimental periods (14 and 21 days). Conclusion Our findings showed that CH induces cell proliferation and improves early mineralization, whereas mTAP was found cytotoxic and reduced the mineralization potential in vitro of APCs.


Asunto(s)
Humanos , Irrigantes del Conducto Radicular/farmacología , Hidróxido de Calcio/farmacología , Papila Dental/citología , Antibacterianos/farmacología , Sales de Tetrazolio , Factores de Tiempo , Ciprofloxacina/farmacología , Cefaclor/farmacología , Diferenciación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Reproducibilidad de los Resultados , Análisis de Varianza , Papila Dental/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Formazáns , Metronidazol/farmacología
2.
Pakistan Journal of Pharmaceutical Sciences. 2011; 24 (3): 303-313
en Inglés | IMEMR | ID: emr-129856

RESUMEN

The effect of temperature stresses on Cefaclor suspensions under different storage conditions for a duration of 14 days was tested. The degradation of Cefaclor was determined on the 2[nd], 7[th] and 14[th] day after reconstitution using a sensitive and precise Reversed phase High Performance Liquid Chromatographic [RP-HPLC] method. The RSD values for Forticef, Midocef, Ceclor, Cefabac and Cloracef, indicated a good precision of the RP-HPLC method. The limit of detection [LOD] and the limit of quantification [LOQ] were found 0.008 mg/ml and 0.03mg/ml respectively. The antimicrobial effect of Cefaclor suspension was also tested against pathogenic bacteria using the cylinder diffusion method. The RSD values range of the antimicrobial assay for all the Cefaclor compounds were 1.47-3.7%. The LOD and LOQ were 0.2mg/ml and Img/ml respectively. During the normal use of Ceclor, Midocef, and Forticef the loss of activity and the degradation were less than 5% on the 14[th] day of preservation at 4°C. However, the percentage of degradation for Cefabac and Cloracef on the 14th day reached 5 and 6%, respectively. Statistical multiple comparison between the effect of 4°C and 25°C indicated non significant mean differences [P >/= 0.05] for Forticef, Cefabac, Ceclor and Cloraf and significant effect for Midocef [P

Asunto(s)
Humanos , Cefaclor/farmacología , Cefaclor/administración & dosificación , Cromatografía de Fase Inversa/métodos , Pruebas Antimicrobianas de Difusión por Disco/métodos , Estabilidad de Medicamentos , Administración Oral , Suspensiones , Temperatura , Factores de Tiempo , Antibacterianos/química , Antibacterianos/farmacología , Almacenaje de Medicamentos/estadística & datos numéricos
3.
J. pediatr. (Rio J.) ; 73(1): 26-31, jan.-fev. 1997. tab
Artículo en Portugués | LILACS | ID: lil-199616

RESUMEN

Objetivo: Determinar a resistência à ampicilina e outros antimicrobianos de amostras de H. influenzae isoladas de diferentes materiais clínicos. Métodos; As amostras de H. influenzae foram identificadas por cultura com fatores V e X e prova do ácido amino-levulínico. A produçäo de ß-lactamase (ßLac) foi detectada pela nitrocefina. A sensibilidade aos antimicrobianos foi testada por difusäo do disco e diluiçäo em meio sólido. O sorotipo b foi testado por coaglutinaçäo. Resultados: De 245 H. influenzae identificados, 155 foram testados para o sorotipo b e 28 por cento (43/155) mostraram-se positivos...


Asunto(s)
Humanos , Masculino , Femenino , Recién Nacido , Lactante , Preescolar , Niño , Haemophilus influenzae/efectos de los fármacos , Farmacorresistencia Microbiana , Resistencia a la Ampicilina , beta-Lactamasas/análisis , Cefaclor/farmacología , Cefotaxima/farmacología , Distribución de Chi-Cuadrado , Cloranfenicol/farmacología , Haemophilus influenzae/aislamiento & purificación
4.
Saudi Medical Journal. 1993; 14 (1): 59-61
en Inglés | IMEMR | ID: emr-30846

RESUMEN

The ability of 383 recent clinical isolates of Haemophilus influenzae to produce beta-lactamase was detected by using cefinase discs. It was found that 8% of the isolates elaborate this enzyme. Since cefaclor supposedly is not inactivated by beta-lactamases of H. influenzae, we studied the in vitro activity of this cephalosporin and compared it with other commonly used antimicrobial agents against isolates of H. influenzae from 383 patients at a tertiary care referral hospital in Riyadh, Saudi Arabia. Cefaclor was found to be most active, inhibiting 98% of the isolates tested, followed by amoxycillin/clavulanic acid and gentamicin [95%], chloramphenicol [93%], cephalothin [90%], ampicillin [87%], tetracycline [77%] trimethoprim-sulphamethoxazole [65%] and erythromycin [47%]


Asunto(s)
beta-Lactamasas/biosíntesis , Cefaclor/farmacología , Antibacterianos/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA